Canopy Growth Posts 22% Revenue Growth, Narrows Adjusted EBITDA Loss to C$2.9M
CGC is trading near its 52-week low of $0.641 (7.6% above the low).
Summary
Canopy Growth reported Q2 FY2027 net revenue of C$81.4M, up 22% year over year, with the cannabis segment up 30% to C$66.2M. International markets cannabis revenue jumped 141% to C$12.3M on strong medical sales in Germany and Poland, while Canada adult-use rose 17% and Canada medical rose 18%. The adjusted EBITDA loss narrowed to C$2.9M from C$3.0M, and free cash outflow improved to C$15.5M from C$19.2M. The reported net loss widened to C$40.7M from C$5.0M, driven by C$35.8M of non-cash fair value charges on Canopy USA assets, and gross margin slipped to 29% from 33% partly on a lower Veterans Affairs reimbursement rate. Management said it is within reach of positive adjusted EBITDA during fiscal 2027. The company also carries a Nasdaq minimum-bid deficiency with a deadline to regain compliance, and shareholders have authorized a reverse split at board discretion. The earnings call is at 10:00 AM ET today.
At the time of this announcement, CGC was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $301.2M. The 52-week trading range was $0.64 to $2.38. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.